Cargando…
Relevance of CYP2C9 Function in Valproate Therapy
BACKGROUND: Genetic polymorphisms of drug metabolizing enzymes can substantially modify the pharmacokinet-ics of a drug and eventually its efficacy or toxicity; however, inferring a patient’s drug metabolizing capacity merely from his or her genotype can lead to false prediction. Non-genetic host fa...
Autores principales: | Monostory, Katalin, Nagy, Andrea, Tóth, Katalin, Bűdi, Tamás, Kiss, Ádám, Déri, Máté, Csukly, Gábor |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Bentham Science Publishers
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6341495/ https://www.ncbi.nlm.nih.gov/pubmed/29119932 http://dx.doi.org/10.2174/1570159X15666171109143654 |
Ejemplares similares
-
Adverse events in a newborn on valproate therapy due to loss-of-function mutations in CYP2C9
por: Nagy, Andrea, et al.
Publicado: (2015) -
Association of clozapine-related metabolic disturbances with CYP3A4 expression in patients with schizophrenia
por: Menus, Ádám, et al.
Publicado: (2020) -
Optimization of Clonazepam Therapy Adjusted to Patient’s CYP3A Status and NAT2 Genotype
por: Tóth, Katalin, et al.
Publicado: (2016) -
Potential Role of Patients’ CYP3A-Status in Clozapine Pharmacokinetics
por: Tóth, Katalin, et al.
Publicado: (2017) -
Impact of genetic and non-genetic factors on hepatic CYP2C9 expression and activity in Hungarian subjects
por: Fekete, Ferenc, et al.
Publicado: (2021)